![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Raloxifene Cuts Risk of Certain Type of Breast Cancer
Raloxifene Cuts Risk of Certain Type of Breast Cancer
June 11, 2008
A new analysis finds that those who took raloxifene (Evista) regularly over a number of years were less likely to develop invasive estrogen-receptor (ER) positive breast cancer, compared with women who did not take the drug.
U.S. News & World Report
U.S. News & World Report
Upcoming Events
-
21Oct